The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback